26 research outputs found
Encapsulation of immunoadjuvant [14c]peptidoglycan monomer into liposomes. Effect of metabolism and immune response in mice.
Antitumor and antimetastatic activity of the immunoadjuvant peptidoglycan monomer PGM in mice bearing MCa mammary carcinoma
Immunotherapy of Lewis lung carcinoma with hydrosoluble peptidoglycan monomer (PGM)
The water-soluble peptidoglycan monomer (PGM) isolated from the culture fluid of Brevibacterium divaricatum, which has immunostimulating activity, has been examined for its antitumor effects in C57BL mice bearing Lewis lung carcinoma. The formation of spontaneous lung metastases from SC tumor implants is significantly inhibited. The growth of SC primary tumors, including advanced ones, is also significantly inhibited, though to a less pronounced extent than the growth of metastases. The effects on metastases are evident with all treatment schedules used, whereas those on SC primary tumors are treatment schedule-dependent. The treatment with PGM was found to be therapeutically useful when combined with surgical removal of IM implants; in conditions where a single post-operative treatment was ineffective, combined post-operative and immediately pre-operative administration of PGM significantly increased (by 40\%) the survival time of treated animals over that of controls undergoing surgery only
The metabolic fate of 14c-labeled peptidoglycan monomer in mice. I. Identification of the monomer and the corresponding pentapeptide in urine.
ADAMANTYL ENTHALTENDE TRIPEPTIDE, DEREN DERIVATE UND HYDROCHLORIDE, DEREN HERSTELLUNG UND BENUTZUNG
New adamantyl comprising tripeptides, derivatives and hydrochlorides thereof, their preparation and use
Patient exposure dose in interventional cardiology per clinical and technical complexity levels. Part 1: results of the VERIDIC project
Background: Patients can be exposed to high skin doses during complex interventional cardiology (IC) procedures. Purpose: To identify which clinical and technical parameters affect patient exposure and peak skin dose (PSD) and to establish dose reference levels (DRL) per clinical complexity level in IC procedures. Material and Methods: Validation and Estimation of Radiation skin Dose in Interventional Cardiology (VERIDIC) project analyzed prospectively collected patient data from eight European countries and 12 hospitals where percutaneous coronary intervention (PCI), chronic total occlusion PCI (CTO), and transcatheter aortic valve implantation (TAVI) procedures were performed. A total of 62 clinical complexity parameters and 31 technical parameters were collected, univariate regressions were performed to identify those parameters affecting patient exposure and define DRL accordingly. Results: Patient exposure as well as clinical and technical parameters were collected for a total of 534 PCI, 219 CTO, and 209 TAVI. For PCI procedures, body mass index (BMI), number of stents ≥2, and total stent length >28 mm were the most prominent clinical parameters, which increased the PSD value. For CTO, these were total stent length >57 mm, BMI, and previous anterograde or retrograde technique that failed in the same session. For TAVI, these were male sex, BMI, and number of diseased vessels. DRL values for Kerma-area product (PKA), air kerma at patient entrance reference point (Ka,r), fluoroscopy time (FT), and PSD were stratified, respectively, for 14 clinical parameters in PCI, 10 in CTO, and four in TAVI. Conclusion: Prior knowledge of the key factors influencing the PSD will help optimize patient radiation protection in IC